Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2009, Article ID 737282, 6 pages
http://dx.doi.org/10.1155/2009/737282
Review Article

Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy Perspectives

1Cardiology Unit, “San Camillo de Lellis” Hospital, Manfredonia, Foggia, Italy
2Cardiology Unit, University of Foggia, Foggia, Italy
3Cardiology Unit, Catholic University, Roma, Italy
4Department of Biomedical Sciences, University of Chieti, Italy

Received 2 April 2009; Revised 15 July 2009; Accepted 28 October 2009

Academic Editor: Muzamil Ahmad

Copyright © 2009 Graziano Riccioni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. J. Piper, “Formation and actions of leukotrienes,” Physiological Reviews, vol. 64, no. 2, pp. 744–761, 1984. View at Google Scholar
  2. M. Peters-Golden and W. R. Henderson Jr., “Leukotrienes,” The New England Journal of Medicine, vol. 357, no. 18, pp. 1841–1854, 2007. View at Publisher · View at Google Scholar · View at PubMed
  3. B. Samuelsson, S.-E. Dahlen, J. A. Lindgren, C. A. Rouzer, and C. N. Serhan, “Leukotrienes and lipoxins: structures, biosynthesis, and biological effects,” Science, vol. 237, no. 4819, pp. 1171–1176, 1987. View at Google Scholar
  4. G. Riccioni, T. Bucciarelli, B. Mancini, C. Di Ilio, and N. D'Orazio, “Antileukotriene drugs: clinical application, effectiveness and safety,” Current Medicinal Chemistry, vol. 14, no. 18, pp. 1966–1977, 2007. View at Publisher · View at Google Scholar
  5. G. Riccioni, C. Di Ilio, P. Conti, T. C. Theoharides, and N. D'Orazio, “Brief review: advances in therapy with antileukotriene drugs,” Annals of Clinical and Laboratory Science, vol. 34, no. 4, pp. 379–387, 2004. View at Google Scholar
  6. M. Back, “Inflammatory signaling through leukotriene receptors in atherosclerosis,” Current Atherosclerosis Reports, vol. 10, no. 3, pp. 244–251, 2008. View at Publisher · View at Google Scholar
  7. M. Back, “Leukotriene signaling in atherosclerosis and ischemia,” Cardiovascular Drugs and Therapy, vol. 23, no. 1, pp. 41–48, 2009. View at Publisher · View at Google Scholar · View at PubMed
  8. L. Zhao, M. P. Moos, R. Gräbner et al., “The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm,” Nature Medicine, vol. 10, no. 9, pp. 966–973, 2004. View at Publisher · View at Google Scholar · View at PubMed
  9. N. Ahluwalia, A. Y. Lin, A. M. Tager et al., “Inhibited aortic aneurysm formation in BLT1-deficient mice,” The Journal of Immunology, vol. 179, no. 1, pp. 691–697, 2007. View at Google Scholar
  10. M. Back, D.-X. Bu, R. Bränström, Y. Sheikine, Z.-Q. Yan, and G. K. Hansson, “Leukotriene B4 signaling through NF-κB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 48, pp. 17501–17506, 2005. View at Publisher · View at Google Scholar · View at PubMed
  11. O. Rådmark and B. Samuelsson, “5-lipoxygenase: mechanisms of regulation,” Journal of Lipid Research, vol. 50, pp. S40–S45, 2009. View at Publisher · View at Google Scholar · View at PubMed
  12. X. Chen, S. Wang, N. Wu, and C. S. Yang, “Leukotriene A4 hydrolase as a target for cancer prevention and therapy,” Current Cancer Drug Targets, vol. 4, no. 3, pp. 267–283, 2004. View at Publisher · View at Google Scholar
  13. C. D. Funk and T. Cyrus, “12/15-lipoxygenase, oxidative modification of LDL and atherogenesis,” Trends in Cardiovascular Medicine, vol. 11, no. 3-4, pp. 116–124, 2001. View at Publisher · View at Google Scholar
  14. C. D. Funk, “Leukotriene modifiers as potential therapeutics for cardiovascular disease,” Nature Reviews Drug Discovery, vol. 4, no. 8, pp. 664–672, 2005. View at Publisher · View at Google Scholar · View at PubMed
  15. M. A. Gimbrone, “Vascular endothelium in health and disease,” in Molecular Cardiovascular Medicine, E. Haber, Ed., pp. 67B–70B, Scientific American Medicine, New York, NY, USA, 1995. View at Google Scholar
  16. M. A. Gimbrone, N. Kume, and M. I. Cybulsky, “Vascular endothelium dysfunction and the pathogenesis of atherosclerosis,” in Atherosclerosis Reviews, P. C. Weber and A. Leaf, Eds., Raven Press, New York, NY, USA, 1993. View at Google Scholar
  17. T. Michel and O. Feron, “Nitric oxide synthases: which, where, how, and why?” The Journal of Clinical Investigation, vol. 100, no. 9, pp. 2146–2152, 1997. View at Google Scholar
  18. J. Maclouf, G. Folco, and C. Patrono, “Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease,” Thrombosis and Haemostasis, vol. 79, no. 4, pp. 691–705, 1998. View at Google Scholar
  19. M. Yanagisawa, H. Kurihara, S. Kimura, K. Goto, and T. Masaki, “A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels,” Journal of Hypertension, vol. 6, supplement 4, pp. S188–S191, 1988. View at Google Scholar
  20. L. K. Jennings, “Role of platelets in atherothrombosis,” American Journal of Cardiology, vol. 103, 3 supplement, pp. 4A–10A, 2009. View at Publisher · View at Google Scholar · View at PubMed
  21. H. Harizi, J.-B. Corcuff, and N. Gualde, “Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology,” Trends in Molecular Medicine, vol. 14, no. 10, pp. 461–469, 2008. View at Publisher · View at Google Scholar · View at PubMed
  22. V. Capra, M. D. Thompson, A. Sala, D. E. Cole, G. Folco, and G. E. Rovati, “Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends,” Medicinal Research Reviews, vol. 27, no. 4, pp. 469–527, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. A. M. Tagerand and A. D. Luster, “BLT1 and BLT2: the leukotriene B(4) receptors,” Prostaglandins Leukot Essent Fatty Acids, vol. 69, pp. 123–134, 2003. View at Google Scholar
  24. A. J. Harmar, R. A. Hills, E. M. Rosser et al., “IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels,” Nucleic Acids Research, vol. 37, supplement 1, pp. D680–D685, 2009. View at Publisher · View at Google Scholar · View at PubMed
  25. T. Yokomizo, T. Izumi, K. Chang, Y. Takuwa, and T. Shimizu, “A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis,” Nature, vol. 387, no. 6633, pp. 620–624, 1997. View at Publisher · View at Google Scholar · View at PubMed
  26. T. Yokomizo, K. Kato, K. Terawaki, T. Izumi, and T. Shimizu, “A second leukotriene B4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders,” Journal of Experimental Medicine, vol. 192, no. 3, pp. 421–431, 2000. View at Publisher · View at Google Scholar
  27. T. Yokomizo, K. Kato, H. Hagiya, T. Izumi, and T. Shimizu, “Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2,” The Journal of Biological Chemistry, vol. 276, no. 15, pp. 12454–12459, 2001. View at Publisher · View at Google Scholar · View at PubMed
  28. K. R. Lynch, G. P. O'Neill, Q. Liu et al., “Characterization of the human cysteinyl leukotriene CysLT1 receptor,” Nature, vol. 399, no. 6738, pp. 789–793, 1999. View at Publisher · View at Google Scholar · View at PubMed
  29. H. M. Sarau, S. Mong, J. J. Foley, H. L. Wu, and S. T. Crooke, “Identification and characterization of leukotriene D4 receptors and signal transduction processes in rat basophilic leukemia cells,” The Journal of Biological Chemistry, vol. 262, no. 9, pp. 4034–4041, 1987. View at Google Scholar
  30. C. E. Heise, B. F. O'Dowd, D. J. Figueroa et al., “Characterization of the human cysteinyl leukotriene 2 receptor,” The Journal of Biological Chemistry, vol. 275, no. 39, pp. 30531–30536, 2000. View at Google Scholar
  31. J. Takasaki, M. Kamohara, M. Matsumoto et al., “The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT2 receptor,” Biochemical and Biophysical Research Communications, vol. 274, no. 2, pp. 316–322, 2000. View at Publisher · View at Google Scholar · View at PubMed
  32. H.-P. Nothacker, Z. Wang, Y. Zhu, R. K. Reinscheid, S. H. S. Lin, and O. Civelli, “Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist,” Molecular Pharmacology, vol. 58, no. 6, pp. 1601–1608, 2000. View at Google Scholar
  33. M. Back, “Leukotriene receptors: crucial components in vascular inflammation,” The Scientific World Journal, vol. 7, pp. 1422–1439, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. M. Damian, S. Mary, A. Martin, J.-P. Pin, and J.-L. Banères, “G protein activation by the leukotriene B4 receptor dimer: evidence for an absence of trans-activation,” The Journal of Biological Chemistry, vol. 283, no. 30, pp. 21084–21092, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. M. Damian, A. Martin, D. Mesnier, J.-P. Pin, and J.-L. Banères, “Asymmetric conformational changes in a GPCR dimer controlled by G-proteins,” The EMBO Journal, vol. 25, no. 24, pp. 5693–5702, 2006. View at Publisher · View at Google Scholar · View at PubMed
  36. C. Bandeira-Melo, L. J. Woods, M. Phoofolo, and P. F. Weller, “Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion,” Journal of Experimental Medicine, vol. 196, no. 6, pp. 841–850, 2002. View at Publisher · View at Google Scholar
  37. R. De Caterina and A. Zampolli, “From asthma to atherosclerosis—5-lipoxygenase, leukotrienes, and inflammation,” The New England Journal of Medicine, vol. 350, no. 1, pp. 4–7, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. C. Brink, S.-E. Dahlen, J. Drazen et al., “International union of pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors,” Pharmacological Reviews, vol. 55, no. 1, pp. 195–227, 2003. View at Publisher · View at Google Scholar · View at PubMed
  39. R. Spanbroek, R. Gräbner, K. Lotzer et al., “Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 1238–1243, 2003. View at Publisher · View at Google Scholar · View at PubMed
  40. J. H. Dwyer, H. Allayee, K. M. Dwyer et al., “Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis,” The New England Journal of Medicine, vol. 350, no. 1, pp. 29–37, 2004. View at Publisher · View at Google Scholar · View at PubMed
  41. A. Helgadottir, A. Manolescu, G. Thorleifsson et al., “The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke,” Nature Genetics, vol. 36, no. 3, pp. 233–239, 2004. View at Publisher · View at Google Scholar · View at PubMed
  42. R. J. Aiello, P.-A. Bourassa, S. Lindsey, W. Weng, A. Freeman, and H. J. Showell, “Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 3, pp. 443–449, 2002. View at Publisher · View at Google Scholar
  43. K. Subbarao, V. R. Jala, S. Mathis et al., “Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 2, pp. 369–375, 2004. View at Publisher · View at Google Scholar · View at PubMed
  44. J. C. Tardif, P. L. L'Allier, R. Ibhraim et al., “Three months of treatment with 5-lipoxygenase inhibitor VIA-2291 in patients with recent acute coronary syndrome,” Circulation, vol. 118, pp. 2309–2317, 2008. View at Google Scholar
  45. S. Xu, B. M. McKeever, D. Wisniewski et al., “Expression, purification and crystallization of human 5-lipoxygenase-activating protein with leukotriene-biosynthesis inhibitors,” Acta Crystallographica Section F, vol. 63, no. 12, pp. 1054–1057, 2007. View at Publisher · View at Google Scholar · View at PubMed
  46. A. D. Ferguson, B. M. McKeever, S. Xu et al., “Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein,” Science, vol. 317, no. 5837, pp. 510–512, 2007. View at Publisher · View at Google Scholar · View at PubMed
  47. K. A. McGill and W. W. Busse, “Zileuton,” The Lancet, vol. 348, no. 9026, pp. 519–524, 1996. View at Publisher · View at Google Scholar
  48. “Zileuton for asthma,” The Medical Letter on Drugs and Therapeutics, vol. 39, no. 995, pp. 18–19, 1997.
  49. S. C. Lazarus, T. Lee, J. P. Kemp et al., “Safety and clinical efficacy of zileuton in patients with chronic asthma,” American Journal of Managed Care, vol. 4, supplement 6, pp. 841–848, 1998. View at Google Scholar
  50. J. L. Witztum, “The oxidation hypothesis of atherosclerosis,” The Lancet, vol. 344, no. 8925, pp. 793–795, 1994. View at Publisher · View at Google Scholar
  51. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar
  52. A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, pp. 233–241, 2000. View at Google Scholar
  53. M. Mehrabian, J. Wong, X. Wang et al., “Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia,” Circulation Research, vol. 89, no. 2, pp. 125–130, 2001. View at Google Scholar
  54. M. Mehrabian, H. Allayee, J. Wong et al., “Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice,” Circulation Research, vol. 91, no. 2, pp. 120–126, 2002. View at Publisher · View at Google Scholar
  55. R. Spanbroek, R. Gräbner, K. Lotzer et al., “Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 3, pp. 1238–1243, 2003. View at Publisher · View at Google Scholar · View at PubMed
  56. J. H. Dwyer, H. Allayee, K. M. Dwyer et al., “Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis,” The New England Journal of Medicine, vol. 350, no. 1, pp. 29–37, 2004. View at Publisher · View at Google Scholar · View at PubMed
  57. A. Helgadottir, A. Manolescu, G. Thorleifsson et al., “The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke,” Nature Genetics, vol. 36, no. 3, pp. 233–239, 2004. View at Publisher · View at Google Scholar · View at PubMed
  58. A. Helgadottir, S. Gretarsdottir, D. St. Clair et al., “Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population,” American Journal of Human Genetics, vol. 76, no. 3, pp. 505–509, 2005. View at Publisher · View at Google Scholar · View at PubMed
  59. A. Helgadottir, A. Manolescu, A. Helgason et al., “A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction,” Nature Genetics, vol. 38, no. 1, pp. 68–74, 2006. View at Publisher · View at Google Scholar · View at PubMed
  60. K. Lotzer, C. D. Funk, and A. J. R. Habenicht, “The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis,” Biochimica et Biophysica Acta, vol. 1736, no. 1, pp. 30–37, 2005. View at Publisher · View at Google Scholar · View at PubMed
  61. O. Rådmark and B. Samuelsson, “5-lipoxygenase: regulation and possible involvement in atherosclerosis,” Prostaglandins and Other Lipid Mediators, vol. 83, no. 3, pp. 162–174, 2007. View at Publisher · View at Google Scholar · View at PubMed
  62. R. Y. Cao, T. St. Amand, R. Gräbner, A. J.R. Habenicht, and C. D. Funk, “Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice,” Atherosclerosis, vol. 203, no. 2, pp. 395–400, 2009. View at Publisher · View at Google Scholar · View at PubMed
  63. H. Hakonarson, S. Thorvaldsson, A. Helgadottir et al., “Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial,” Journal of the American Medical Association, vol. 293, no. 18, pp. 2245–2256, 2005. View at Publisher · View at Google Scholar · View at PubMed
  64. H. Hakonarson, “Role of FLAP and PDE4D in myocardial infarction and stroke: target discovery and future treatment options,” Current Treatment Options in Cardiovascular Medicine, vol. 8, no. 3, pp. 183–192, 2006. View at Publisher · View at Google Scholar
  65. T. J. Mocatta, A. P. Pilbrow, V. A. Cameron et al., “Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction,” Journal of the American College of Cardiology, vol. 49, no. 20, pp. 1993–2000, 2007. View at Publisher · View at Google Scholar · View at PubMed
  66. S. Q. Khan, D. Kelly, P. Quinn, J. E. Davies, and L. L. Ng, “Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction,” Heart, vol. 93, no. 7, pp. 826–831, 2007. View at Publisher · View at Google Scholar · View at PubMed
  67. M. Back, “Leukotrienes: potential therapeutic targets in cardiovascular diseases,” Bulletin de l'Academie Nationale de Medecine, vol. 190, no. 7, pp. 1511–1518, 2006. View at Google Scholar